NZ563301A - Use of docosahexaenoic glycerides for the treatment of tumoral diseases - Google Patents

Use of docosahexaenoic glycerides for the treatment of tumoral diseases

Info

Publication number
NZ563301A
NZ563301A NZ563301A NZ56330106A NZ563301A NZ 563301 A NZ563301 A NZ 563301A NZ 563301 A NZ563301 A NZ 563301A NZ 56330106 A NZ56330106 A NZ 56330106A NZ 563301 A NZ563301 A NZ 563301A
Authority
NZ
New Zealand
Prior art keywords
fatty acids
use according
oil
dha
weight
Prior art date
Application number
NZ563301A
Other languages
English (en)
Inventor
Pedrol Joan Carles Domingo
Original Assignee
Proyecto Empresarial Brudy Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto Empresarial Brudy Sl filed Critical Proyecto Empresarial Brudy Sl
Publication of NZ563301A publication Critical patent/NZ563301A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ563301A 2005-05-12 2006-04-26 Use of docosahexaenoic glycerides for the treatment of tumoral diseases NZ563301A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200501141A ES2264886B1 (es) 2005-05-12 2005-05-12 Utilizacion de acido docosahexaenoico para el tratamiento de enfermedades tumorales.
PCT/EP2006/061833 WO2006120120A1 (en) 2005-05-12 2006-04-26 Use of docosahexaenoic glycerides for the treatment of tumorous diseases

Publications (1)

Publication Number Publication Date
NZ563301A true NZ563301A (en) 2010-08-27

Family

ID=36809521

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ563301A NZ563301A (en) 2005-05-12 2006-04-26 Use of docosahexaenoic glycerides for the treatment of tumoral diseases

Country Status (12)

Country Link
US (3) US20080207947A1 (enExample)
EP (1) EP1881824B1 (enExample)
JP (2) JP5893235B2 (enExample)
CA (1) CA2614192C (enExample)
DK (1) DK1881824T3 (enExample)
ES (2) ES2264886B1 (enExample)
IL (1) IL187274A (enExample)
NO (1) NO336953B1 (enExample)
NZ (1) NZ563301A (enExample)
PL (1) PL1881824T3 (enExample)
PT (1) PT1881824E (enExample)
WO (1) WO2006120120A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2264886B1 (es) * 2005-05-12 2008-02-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento de enfermedades tumorales.
CN101262863B (zh) * 2005-07-08 2016-08-31 Dsmip资产公司 用于治疗痴呆和前痴呆相关病症的多不饱和脂肪酸
ES2277557B1 (es) 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
KR101256448B1 (ko) 2005-12-21 2013-04-19 브루디 테크놀로지 에스엘 세포의 산화적 손상과 연관된 병리상태를 치료하기 위한ｄｈａ, ｅｐａ 또는 ｄｈａ 유래의 ｅｐａ의 용도
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
CA2708679C (en) * 2007-12-19 2016-11-15 Prometic Biosciences Inc. Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer
WO2011103514A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha triglyceride emulsions
US20110200645A1 (en) * 2010-02-18 2011-08-18 Martek Biosciences Corporation DHA Free Fatty Acid Emulsions
WO2011103510A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha ester emulsions
EP2599485B1 (en) * 2010-07-26 2019-02-20 FUJIFILM Corporation Fat-containing composition and oral formulation containing same
ES2753387T3 (es) 2013-04-22 2020-04-08 Smartfish As Uso de una composición que comprende aceite de pescado y zumo para el tratamiento y/o tratamiento posterior del cáncer
KR101665253B1 (ko) 2015-06-19 2016-10-25 순천향대학교 산학협력단 도코사헥사에노산 및 트리아신 씨를 포함하는 것을 특징으로 하는 자궁내막암 치료 및 예방용 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3721137A1 (de) * 1987-06-26 1989-01-05 Dietl Hans Fettemulsion zur intravenoesen anwendung
US5147854A (en) * 1990-05-22 1992-09-15 Hoffmann-La Roche Inc. Tgf-b compositions and method
JP2572692B2 (ja) * 1991-07-24 1997-01-16 ボーソー油脂 株式会社 ドコサヘキサエン酸トリグリセリドの製造法
JPH05139968A (ja) * 1991-11-14 1993-06-08 Sagami Chem Res Center メダラシン活性促進剤
JPH0616548A (ja) * 1992-06-30 1994-01-25 Sagami Chem Res Center 組織異常増殖抑制剤
JPH06116585A (ja) * 1992-10-09 1994-04-26 Kanegafuchi Chem Ind Co Ltd 油脂の精製方法
JP3526632B2 (ja) * 1994-08-22 2004-05-17 旭化成ケミカルズ株式会社 高度不飽和脂肪酸含有油脂
JPH1057086A (ja) * 1996-08-20 1998-03-03 Asahi Chem Ind Co Ltd 高濃度ドコサヘキサエン酸モノグリセリドの製造方法
AU5928599A (en) * 1999-09-09 2001-04-10 Efa Sciences Llc. Methods for treating cell proliferative disorders including cancer
JP2002180082A (ja) * 2000-12-11 2002-06-26 Maruha Corp 摂取物
US20040052837A1 (en) * 2002-06-27 2004-03-18 William Stillwell Lipid conjugated anti-cancer drugs and methods of use thereof
ES2264886B1 (es) * 2005-05-12 2008-02-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento de enfermedades tumorales.

Also Published As

Publication number Publication date
US20160193175A1 (en) 2016-07-07
US20170333381A9 (en) 2017-11-23
CA2614192C (en) 2014-03-18
IL187274A0 (en) 2008-06-05
ES2264886B1 (es) 2008-02-01
EP1881824A1 (en) 2008-01-30
PL1881824T3 (pl) 2015-06-30
DK1881824T3 (en) 2015-02-23
JP5893235B2 (ja) 2016-03-23
WO2006120120A1 (en) 2006-11-16
HK1113319A1 (en) 2008-10-03
CA2614192A1 (en) 2006-11-16
ES2531599T3 (es) 2015-03-17
JP2008540484A (ja) 2008-11-20
IL187274A (en) 2011-11-30
EP1881824B1 (en) 2014-12-24
US20080207947A1 (en) 2008-08-28
NO20076382L (no) 2008-02-08
US9271954B2 (en) 2016-03-01
PT1881824E (pt) 2015-03-26
ES2264886A1 (es) 2007-01-16
JP6038841B2 (ja) 2016-12-07
NO336953B1 (no) 2015-11-30
US20090318553A1 (en) 2009-12-24
JP2014208677A (ja) 2014-11-06

Similar Documents

Publication Publication Date Title
US9271954B2 (en) Use of docosahexaenoic glycerides for the treatment of tumorous diseases
Hashimoto et al. Docosahexaenoic acid: one molecule diverse functions
US11253497B2 (en) Use of derivatives of polyunsaturated fatty acids as medicaments
EP1275399B1 (en) Method and preparation for preventing and/or treating vascular disorders and secondary disorders associated therewith
US5925669A (en) Carrier compositions for anti-neoplastic drugs
JP5711140B2 (ja) 薬物として使用するためのシス−一不飽和脂肪酸のα誘導体
EP1909800B1 (de) Acylglycerophospholipide zur behandlung von krebs-begleiterscheinungen
KR102272558B1 (ko) 식이 오메가-3 보충제에서 아스피린의 사용 없이 아스피린-유발된 레졸빈의 생산방법
HK1113319B (en) Use of docosahexaenoic triglycerides for the treatment of tumorous diseases
WO2006054316A1 (en) Method(s) of preparation, stabilization, composition, and administration of gamma-linolenic acid for brain tumors
FR2946534A1 (fr) Utilisation d'alkylglycerols pour la preparation de medicaments.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 26 APR 2016 BY CPA GLOBAL

Effective date: 20130315

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 APR 2017 BY CPA GLOBAL

Effective date: 20160318

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 APR 2018 BY CPA GLOBAL

Effective date: 20170311

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 APR 2019 BY CPA GLOBAL

Effective date: 20180315

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 APR 2020 BY RENEWALSDESK LIMITED

Effective date: 20190408

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 APR 2021 BY RENEWALSDESK LIMITED

Effective date: 20200427

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 APR 2022 BY RENEWALSDESK

Effective date: 20210420

LAPS Patent lapsed